Onesource says DDC capacity will triple by FY28
In short
Onesource Specialty Pharma said its DDC capacity will triple by financial year 2028. It said two cartridge lines are starting commercial operations and line 3 FAT has been completed.
This matters because the company says its biologics platform is getting stronger with new customer wins and a fuller pipeline. The snippet does not give the earnings numbers or explain the stock jump in detail.
What the reporting says
Onesource Specialty Pharma said in its investor presentation that DDC capacity will triple for financial year 2028 as two cartridge lines begin commercial operations and line 3 FAT is completed. The company also said its biologics platform is gaining momentum with new customer wins and a robust funnel. The reporting does not provide earnings figures, and the immediate stock move is not detailed in the source snippet.
Why it matters
Onesource Specialty Pharma said in its investor presentation that DDC capacity will triple by financial year 2028, helped by two cartridge lines entering commercial operations and completion of line 3 FAT. It also said its biologics platform is gaining momentum through new customer wins and a robust funnel. The source does not include the earnings figures behind the reported stock rise or any updated financial details.